80 Fungal microbes could play a bigger role in cancer development and treatment than previously thought, according to new research exploring the link between fungi, immunosenescence, and tumour progression. Scientists have found that the presence of fungi within the human microbiome may significantly influence cancer outcomes by interacting with the immune system and altering the tumour microenvironment. The findings were published in the journal Seminars in Cancer Biology. The study highlights how immunosenescence, the gradual decline of the immune system with age, is closely intertwined with cancer progression. As immune function deteriorates, the body becomes more susceptible to infections, and the regulation of tumour growth weakens. Researchers found that fungi may contribute to this process by secreting metabolites that can either promote or suppress tumour development. Some fungal species appear to create a more favourable environment for cancer cells, while others could potentially enhance immune responses against tumours. One of the key findings of the study concerns the way fungi interact with other microorganisms within the body. The research suggests that certain fungi engage in complex relationships with bacteria and viruses, collectively influencing the behaviour of cancer cells. Fungal metabolites, including aflatoxins and candidalysin, have been found to affect cellular processes that drive tumour growth and metastasis. Additionally, these interactions appear to modulate immune responses, which could have implications for both cancer progression and treatment effectiveness. The role of fungi in cancer treatment was also explored, with the study indicating that fungal activity may impact the success of various therapies. Researchers examined how fungi influence surgical outcomes, chemotherapy resistance, radiotherapy responses, and immunotherapy efficacy. In some cases, fungi appeared to undermine treatment by weakening immune responses or promoting inflammation. For instance, certain fungal species have been linked to increased resistance to chemotherapy in colon cancer patients, while others may reduce the effectiveness of immunotherapy by altering immune cell function. Despite the emerging evidence linking fungi and cancer, the study acknowledges significant challenges in this area of research. One of the main difficulties is detecting and analysing fungal communities within tumours, as their abundance is typically low compared to bacteria. Current sequencing methods face limitations in accurately identifying and quantifying fungal species, which makes it difficult to determine their precise role in cancer development and treatment outcomes. Scientists emphasise the need for improved detection techniques to better understand the influence of fungi on tumour biology. The study also suggests that fungi could serve as potential biomarkers for cancer diagnosis and prognosis. Differences in fungal compositions have been observed between healthy individuals and cancer patients, raising the possibility that specific fungal signatures could be used to detect cancer at an earlier stage. However, more research is required to validate these findings and assess the reliability of fungal biomarkers in clinical settings. With immunosenescence playing a key role in ageing-related cancers, researchers propose that targeting fungi could be a novel strategy to enhance treatment responses. Modifying fungal populations through diet, probiotics, or antifungal therapies might offer new opportunities to improve cancer outcomes. While these ideas remain largely theoretical, they provide a foundation for further investigation into how fungi can be harnessed to support cancer treatment strategies.